MDT

95.95

+0.39%↑

VEEV

284.17

-1.12%↓

A

136.6

-1.56%↓

HQY

93.73

+1.23%↑

PHR.US

22.42

+1.82%↑

MDT

95.95

+0.39%↑

VEEV

284.17

-1.12%↓

A

136.6

-1.56%↓

HQY

93.73

+1.23%↑

PHR.US

22.42

+1.82%↑

MDT

95.95

+0.39%↑

VEEV

284.17

-1.12%↓

A

136.6

-1.56%↓

HQY

93.73

+1.23%↑

PHR.US

22.42

+1.82%↑

MDT

95.95

+0.39%↑

VEEV

284.17

-1.12%↓

A

136.6

-1.56%↓

HQY

93.73

+1.23%↑

PHR.US

22.42

+1.82%↑

MDT

95.95

+0.39%↑

VEEV

284.17

-1.12%↓

A

136.6

-1.56%↓

HQY

93.73

+1.23%↑

PHR.US

22.42

+1.82%↑

Search

Adaptive Biotechnologies Corp

Ouvert

15.49 1.44

Résumé

Variation du prix de l'action

24h

Actuel

Min

15.16

Max

15.62

Chiffres clés

By Trading Economics

Revenu

4.2M

-26M

Ventes

6.4M

59M

Marge bénéficiaire

-43.467

Employés

619

EBITDA

11M

-18M

Recommandations

By TipRanks

Recommandations

Achat Fort

Prévisions sur 12 Mois

-1.12% downside

Dividendes

By Dow Jones

Prochains Résultats

6 nov. 2025

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

546M

2.2B

Ouverture précédente

14.05

Clôture précédente

15.49

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

Adaptive Biotechnologies Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

13 oct. 2025, 21:45 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million -- Update

13 oct. 2025, 21:07 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs to Acquire Industry Ventures for Up to $965 Million

13 oct. 2025, 17:03 UTC

Principaux Mouvements du Marché

Canaan ADRs Climb on Launch of Gas-to-Computing Pilot in Canada

13 oct. 2025, 23:53 UTC

Market Talk

Gold Rises, Buoyed by Bullish Fundamental Backdrop -- Market Talk

13 oct. 2025, 23:39 UTC

Market Talk

Nikkei May Rise, Tracking Wall Street's Gains -- Market Talk

13 oct. 2025, 22:15 UTC

Market Talk

Global Equities Roundup: Market Talk

13 oct. 2025, 22:15 UTC

Market Talk

Precinct Properties NZ's Equity Raising Looks Opportunistic -- Market Talk

13 oct. 2025, 21:57 UTC

Acquisitions, Fusions, Rachats

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 oct. 2025, 21:36 UTC

Market Talk

Global Equities Roundup: Market Talk

13 oct. 2025, 21:36 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

13 oct. 2025, 21:36 UTC

Market Talk

Fletcher's Near-Term Headwinds Don't Cloud Earnings Opportunity -- Market Talk

13 oct. 2025, 21:30 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs to Acquire Industry Ventures for Up to $965M -- Update

13 oct. 2025, 21:06 UTC

Acquisitions, Fusions, Rachats

Goldman Buys $7B Venture-Capital Firm in Latest Asset-Management Bet -- Barrons.com

13 oct. 2025, 20:52 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs to Acquire Industry Ventures for Up to $965M

13 oct. 2025, 20:50 UTC

Market Talk

Tech, Media & Telecom Roundup: Market Talk

13 oct. 2025, 20:35 UTC

Acquisitions, Fusions, Rachats

Goldman Expects to Close Deal in 1Q

13 oct. 2025, 20:34 UTC

Acquisitions, Fusions, Rachats

Industry Ventures Will Be Part of Goldman's External Manager Platform, External Investing Group

13 oct. 2025, 20:33 UTC

Acquisitions, Fusions, Rachats

Industry Ventures Currently Manages $7B of Assets Under Supervision

13 oct. 2025, 20:32 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs: Deal to Include Up to $300M of Additional Contingent Consideration Based on Future Performance Through 2030

13 oct. 2025, 20:31 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs: Consideration to Include $665M Cash and Equity Payable at Closing

13 oct. 2025, 20:29 UTC

Acquisitions, Fusions, Rachats

Goldman Sachs to Buy VC Firm Industry Ventures

13 oct. 2025, 19:05 UTC

Market Talk

Oil Futures Pick Up on Easing U.S.-China Tension -- Market Talk

13 oct. 2025, 18:59 UTC

Market Talk

U.S. Natural Gas Futures Snap Losing Streak -- Market Talk

13 oct. 2025, 18:26 UTC

Market Talk

Precious Metals Close at New Record Highs -- Market Talk

13 oct. 2025, 18:10 UTC

Market Talk

Global Equities Roundup: Market Talk

13 oct. 2025, 18:10 UTC

Market Talk

Broadcom's OpenAI Deal Highlights AI Opportunity -- Market Talk

13 oct. 2025, 17:05 UTC

Market Talk

Global Equities Roundup: Market Talk

13 oct. 2025, 17:05 UTC

Market Talk

OpenAI Deal Offers Huge Upside to Broadcom's Earnings -- Market Talk

13 oct. 2025, 16:03 UTC

Acquisitions, Fusions, Rachats

Umicore Completes Sale, Subsequent Lease-in of Permanent Gold Inventories

13 oct. 2025, 15:35 UTC

Market Talk

Precious Metals Push Record Highs Further -- Market Talk

Comparaison

Variation de prix

Adaptive Biotechnologies Corp prévision

Objectif de Prix

By TipRanks

-1.12% baisse

Prévisions sur 12 Mois

Moyen 15 USD  -1.12%

Haut 20 USD

Bas 11 USD

Basé sur 8 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Achat Fort

8 ratings

7

Achat

1

Maintien

0

Vente

Score Technique

By Trading Central

8.81 / 10.18Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Strong Bullish Evidence

Long Terme

Weak Bullish Evidence

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Adaptive Biotechnologies Corp

Adaptive Biotechnologies Corporation, a commercial-stage company, develops an immune medicine platform for the diagnosis and treatment of various diseases. The company offers immunosequencing platform which combines a suite of proprietary chemistry, computational biology, and machine learning to generate clinical immunomics data to decode the adaptive immune system. It also provides clonoSEQ diagnostic test which detects and monitors the remaining number of cancer cells that are present in a patient's body during and after treatment, known as Minimal Residual Disease (MRD). The company offers products and services for life sciences research, clinical diagnostics, and drug discovery applications. Adaptive Biotechnologies Corporation has strategic collaborations with Genentech, Inc. for the development, manufacture, and commercialization of neoantigen directed T cell therapies for the treatment of a range of cancers; and Microsoft Corporation to develop diagnostic tests for the early detection of various diseases from a single blood test. The company was formerly known as Adaptive TCR Corporation and changed its name to Adaptive Biotechnologies Corporation in December 2011. Adaptive Biotechnologies Corporation was incorporated in 2009 and is headquartered in Seattle, Washington.
help-icon Live chat